SAFETY, PHARMACOKINETICS, AND IMMUNOLOGICAL EFFECTS OF OMILANCOR (BT-11) IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS

Josep Bassaganya-Riera  1     Andrew Leber  1     Nuria Tubau-Juni  1     Jyoti Chauhan  1     Jean-Frédéric Colombel  2     Simon Lichtiger  2     Raquel Hontecillas  2    
1 Landos Biopharma, Inc., Blacksburg, United States
2 Icahn School of Medicine at Mount Sinai, New York, United States

Topic
IBD, Immunology

Session
IBD: Clinical trials III

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing